S. E. Ziganshina

S. E. Ziganshina

Auto-generated profile, based on publicly available information

S. E. Ziganshina

Kirov Research Institute of Hematology and Blood Transfusion

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
EKE. A. Konovalova
E. A. Konovalova
EKE. N. Kalinina
E. N. Kalinina
EKE. S. Kormshchikova
E. S. Kormshchikova
ERE. V. Rosina
E. V. Rosina
SZS. E. Ziganshina
S. E. Ziganshina
IPI. V. Paramonov
I. V. Paramonov
INTRODUCTION. Human hepatitis B immunoglobulins (HBIGs) are produced from the plasma of vaccinated donors and are used to prevent hepatitis B virus infection. The main challenge associated with the quality control and efficacy evaluation of HBIGs is the lack of reference standards certified for the content of antibodies to hepatitis B virus surface antigen (HBsAg). Systematisation and analysis of the relevant experience in HBIG testing and manufacturing will contribute to the development of new approaches to HBIG standardisation.AIM. This study aimed to characterise HBIGs and consider approaches to their standardisation.DISCUSSION. Most HBIGs are developed in Germany (27%), Italy (17%), and the USA (17%) and are formulated for intramuscular (67%), intravenous (30%), and subcutaneous (3%) administration. The potency of HBIGs varies from 50 to 500 IU/mL. There are 3 HBIGs approved in Russia, but the available HBIGs do not fully cover the needs of prevention and treatment providers. The effectiveness of hepatitis B prevention directly depends on the HBIG dose, which is calculated using the potency of the HBIG. Ensuring the accuracy of HBIG potency determination requires a reference standard for anti-HBsAg antibodies certified in international units. The existing international standard for HBIGs has limited commercial availability in the Russian Federation, and the national (pharmacopoeial) reference standard for HBIGs is lacking.CONCLUSIONS. The analysis of information on the currently manufactured HBIGs has identified recent development trends in this pharmaceutical industry sector. The future development and implementation of the national (pharmacopoeial) reference standard for anti-HBsAg antibodies will contribute to improving the quality of HBIGs and, therefore, the effectiveness of preventive immunisation against hepatitis B.

20 August 2025 in Extreme Medicine
Verified
Journal Article
Open access
PDF file
SZS. E. Ziganshina
S. E. Ziganshina
EKE. S. Kormshchikova
E. S. Kormshchikova
EKE. N. Kalinina
E. N. Kalinina
ERE. V. Rosina
E. V. Rosina
EKE. A. Konovalova
E. A. Konovalova
IPI. V. Paramonov
I. V. Paramonov
Лиофилизированная плазма для оказания экстренной трансфузиологической помощи в экстремальных условиях

19 December 2025 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
EKE. S. Kormshchikova
E. S. Kormshchikova
EKE. N. Kalinina
E. N. Kalinina
EKE. A. Konovalova
E. A. Konovalova
ERE. V. Rosina
E. V. Rosina
НВН. С. Вильданова
Н. С. Вильданова
IPI. V. Paramonov
I. V. Paramonov
INTRODUCTION . Pharmaceutical production uses reference standards as an integral part of metrological support for analytical methods. A systematic literature analysis on standardisa­tion of human immunoglobulin preparations, particularly specific and special-purpose ones, will allow evaluating the metrological support in the Russian Federation and identifying new approaches to obtaining and using reference standards to assess specific potency. AIM . This study aimed to analyse published data on the range of reference standards used to evaluate potency of human immunoglobulins in the Russian Federation and abroad. DISCUSSION . PubMed, eLIBRARY.RU, and ConsultantPlus® legal research system showed that the list of international reference standards includes Rh 0 (D), hepatitis B, tetanus, staphylococcal and cytomegalovirus infections, rabies, and smallpox human immunoglobulins. No reference standard is available for human immunoglobulin against tick-borne encephalitis, since no specific human immunoglobulin is produced in the European Union. There is an absolute dependence on the import of international reference standards for assessing the potency of human hepatitis B, cytomegalovirus, and rabies immunoglobulins. Reference standards are typically obtained from ready-to-use batches of medicinal products and then stabilised, bottled under sterile conditions, and lyophilised. The Register of the State Pharmacopoeia of the Russian Federation includes reference standards for Rh 0 (D), anti-tetanus serum, and staphylococcal immunoglobulin. Unlike international reference standards, pharmacopoeial standards are produced as solutions, thus significantly reducing antibody stability. For pharmacopoeial reference standards, statistical uncertainty of the certified value is established in the Russian Federation; however, while certifying international reference standards, their certification is not obligatory. According to literature analysis, the key requirements for reference standards are stability and composition / properties similar to standardised preparations. Russian and foreign certification requirements of reference standards have certain differences. The number of Russian reference standards based on human immunoglobulin G is limited, since they are mostly obtained from horse blood serum. CONCLUSIONS . Russian pharmaceutical industry shows a deficit of national reference standards used for assessing specific potency of human immunoglobulins and donor plasma for their production. Thus, such reference standards should be released as lyophilisates and certified in international units, with an evaluation of statistical uncertainty of the antibody content.